BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The German firms is going to obtain the rights to Biotheus’ “investigational bispecific antibody” named the “BNT327/PM8002,” and use it in its oncology strategy. The advanced clinical asset focuses on ...

In particular, the drug candidate BNT327/PM8002 developed by Biotheus will be a key area of focus after the deal closes. Last year, BioNTech obtained the exclusive global development and ...

More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.